source
- Swiss startup Vaderis raises $152 million to fund Phase 3 trial of rare bleeding disorder therapyVaderis Therapeutics, a 13‑person Swiss biotech, announced a $152 million Series B financing round aimed at advancing its experimental therapy into a Phase 3 study. The company is testing a treatm…
- Former Legend Biotech CEO Ying Huang appointed head of K2 Therapeutics as startup secures $50M seed fundingYing Huang, who led Legend Biotech for seven years and helped develop a top‑selling cell therapy for multiple myeloma, has been named chief executive of K2 Therapeutics. The young company, founded…